Phase I/II study of carboplatin and oral
β
Giuseppe Frasci; Giovanni Persico; Giuseppe Perillo; Giuseppe Comella; Pasquale
π
Article
π
1995
π
John Wiley and Sons
π
English
β 665 KB
Background. A combination of carboplatin (CBDCA) and oral etoposide is better tolerated than, and as effective as, more aggressive chemotherapy regimens in patients with advanced nonsmall cell lung cancer (NSCLC). A Phase 1/11 study was conducted to determine whether the addition of the granulocyte-